

Portulaca Oleracea L. as a Potential Therapeutic Drug Intervention in Ulcerative Colitis: Mechanisms of Action and Clinical Studies

Xiao-Yan Liu^{1,*}, Zi-Xuan Liu^{1,*}, Wei-Wei Tan¹, Wei-Bing Zhang¹, Ya-Li Zhang², Lie Zheng³, Ren-Ye Que¹, Hong-Zhu Wen⁴, Yan-Cheng Dai¹

¹Department of Gastroenterology, Shanghai Traditional Chinese Medicine-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200082, People's Republic of China; ²Institute of Digestive Diseases, Long Hua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, People's Republic of China; ³Department of Gastroenterology, Traditional Chinese Medicine Hospital of Shaanxi Province, Xi'an, 710003, People's Republic of China; ⁴Department of Gastroenterology, Long Hua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, People's Republic of China

*These authors contributed equally to this work

Correspondence: Yan-Cheng Dai; Hong-Zhu Wen, Email daiyancheng2005@126.com; ellawhz@sina.com

Abstract: *Portulaca oleracea* L. (POL) has a long history of medicinal use worldwide, and numerous clinical and experimental studies demonstrated the therapeutic effects of POL and its active ingredients in the treatment of Ulcerative colitis (UC). In this review, we summarized the underlying mechanisms and roles of POL in UC treatment based on experimental and clinical studies. The research articles cited in this study were obtained by employing specific keywords, such as “purslane”, “IBD”, “UC”, “inflammation”, “gut microbiota”, and “intestinal barrier”, in PubMed, Web of Science, Google Scholar, and China National Knowledge Infrastructure databases. Clinical studies found that both POL monotherapy and POL traditional Chinese medicine compound are effective in treating UC. Meanwhile, experimental studies found that POL intervenes in UC by regulating intestinal flora, repairing mucosal barrier, and regulating immune response. Increasing evidence suggests the therapeutic potential of POL in UC treatment.

Keywords: ulcerative colitis, *Portulaca oleracea* L., gut microbiota, intestinal barrier, immunoregulation

Introduction

Ulcerative colitis (UC) is a lifelong chronic non-specific inflammatory bowel disease (IBD), characterized by bloody mucous stools, abdominal pain, diarrhea, and tenesmus. UC lesions primarily occur in the colon and rectum and are limited to the mucosa and submucosa.^{1,2} The incidence of UC is increasing worldwide, with an estimated global prevalence of 5 million cases in 2023.^{1,3} Epidemiological studies found that the incidence and prevalence of UC in some Asian countries had increased by 1.5 to nearly 20-fold in the past four decades.⁴ Current therapeutic agents for UC include 5-aminosalicylic acid, glucocorticoids, immunosuppressants, biologics, and small-molecule agents. However, these drugs are insufficient at targeting the complex pathophysiology of UC, which is highly variable and susceptible to comorbidities, such as infections, thrombosis, and risk of carcinoma.⁵

Traditional Chinese medicine (TCM) preparations have multi-component, multi-target, multi-pathway characteristics, which allow for a comprehensive treatment of several diseases with fewer adverse effects. Therefore, in recent years, TCM has become a research hotspot for the identification of novel drugs for UC treatment.⁶ In TCM, UC is categorized under “Jiu Li” and “Chang Pi”, which are characterized by dampness and heat in the intestines and an imbalance of qi and blood, during the active stage. According to TCM, dampness–heat syndrome of the large intestine is the most common type of UC, which can be treated by clearing heat and transforming dampness and regulating qi and harmonizing blood.^{7,8}

Portulaca oleracea L. (POL) is a representative anti-dysentery TCM herb that is known to clear heat, transform dampness, remove toxins, cool the blood, and stop bleeding. It is cooling and sour and is consumed as a food and medicinal herb. It is also known as a “natural antibiotic”. Additionally, POL has been recorded to treat heat toxic blood dysentery in the TCM books, “Tai Ping Sheng Hui Fang” and “Jing Xiao Chan Bao”.⁹ Modern pharmacological studies found that POL contained flavonoids, alkaloids, fatty acids, terpenoids, polysaccharides, vitamins, sterols, proteins, minerals, and other components, which have anti-inflammatory, immunomodulatory, antibacterial, antiviral, antioxidant, anticarcinogenic, nephroprotective, hepatoprotective, gastrointestinal (GI) protective, metabolic, muscle relaxant, anti-asthmatic, and antioxidant properties.¹⁰

In this review, we summarized the mechanisms of action and clinical research progress of POL in the treatment of UC and indicated directions for subsequent research on the role of POL in UC treatment.

Overview of POL

History of POL in the Treatment of Dysentery

POL, belonging to the Amaranthaceae family, is an annual herb with reddish stems and alternate leaves. It is widely distributed, especially in the tropical and subtropical regions.¹¹ It is used in many countries as a food source as well as a traditional medicine for relieving a wide range of ailments, including GI disorders, respiratory disorders, and liver inflammation.^{12,13} Moreover, Pedanius Dioscorides (40–90 AD), known as the father of pharmacology, described POL (under the name “andrachne”) as an astringent in *De Materia Medica* and recorded it as a treatment for dysentery.¹⁴ In China, POL was first described in the “Collected Notes on the Materia Medica (Ben Cao Jing Ji Zhu)” as having curative effects of clearing heat, removing toxins, dissipating blood, and resolving swelling. Additionally, POL has been recorded to treat infantile malnutrition and dysentery in the “Food Therapy Materia Medica (Shi Liao Ben Cao)” and heat toxic blood dysentery in “Tai Ping Sheng Hui Fang” and “Jing Xiao Chan Bao”. In the Chinese Pharmacopoeia, POL has been recorded to treat heat toxic blood dysentery, swollen welling-abscess and clove sores (Figure 1).










Figure 1 Historical texts documenting the use of *Portulaca oleracea* L. (POL) in the treatment of dysentery.

Active Ingredients of POL










POL primarily contains flavonoids, alkaloids, organic acids, and terpenoids. Kaempferol, myricetin, rutin, luteolin, quercetin, apigenin (API), genistin, and genistein are some of the flavonoids isolated from stems, leaves, and roots of POL.¹⁵ Norepinephrine, dopamine, dopa, uracil, thymine, adenosine, allantoin, N, N-dicyclohexylurea, and N-trans-feruloyltyl tyrosine (dominated by isoquinoline-like structures and indole-like structures of the parent nucleus) as well as cyclic dipeptide alkaloids and amides are a few alkaloid compounds found in POL.¹⁶ α -Linolenic acid, palmitic acid, p-coumaric acid, linoleic acid, stearic acid, ferulic acid, oleic acid, caffeic acid, and oxalic acid are some organic acids found in POL.¹⁷ Purslane monoterpene, lupeol, eleutheroside A, taraxerol, oleanolic acid, and cycloartenol are some terpene constituents reported in POL.¹¹ Other pharmacological compounds found in POL include trans-p-coumaric acid, 7-hydroxycoumarin, bergapten, isopimpinellin, scopoletin, lutein, β -carotene, melatonin, and vitamin C (Table 1).^{18,19}

Table 1 Active Compounds Isolated from POL and Their Structural Formulas

Classification	Chemical component	Part of plant	Molecular Formula	Structural Formula	Reference
Flavonoids	Kaempferol	Whole plant	$C_{15}H_{10}O_6$		[20]
	Apigenin	Leaf and stem	$C_{15}H_{10}O_5$		[20]
	Myricetin	Whole plant	$C_{15}H_{10}O_8$		[20]
	Rutin		$C_{27}H_{30}O_{16}$		[21]
	Luteolin	Whole plant	$C_{15}H_{10}O_6$		[20]
	Quercetin	Whole plant	$C_{15}H_{10}O_7$		[20]










(Continued)

Table I (Continued).

Classification	Chemical component	Part of plant	Molecular Formula	Structural Formula	Reference
	Genistin	Whole plant	$C_{21}H_{20}O_{10}$		[22]
	Genistein	Whole plant	$C_{15}H_{10}O_5$		[22]
Alkaloids	Noradrenalin	Stem, leaf and seed	$C_8H_{11}NO_3$		[23]
	Dopamine	Stem, leaf and seed	$C_8H_{11}NO_2$		[24]
	Dopa		$C_{39}H_{74}NaO_8P$		[25]
	Uracil	Aerial parts	$C_4H_4N_2O_2$		[26]
	Thymine	Aerial parts	$C_5H_6N_2O_2$		[26]
	Adenosine	Whole plant	$C_{10}H_{13}N_5O_4$		[25]
	Allantoin		$C_4H_6N_4O_3$		[27]








(Continued)

Table I (Continued).

Classification	Chemical component	Part of plant	Molecular Formula	Structural Formula	Reference
	N, N-dicyclohexylurea		$C_{13}H_{24}N_2O$		[27]
	N-trans-feruloyltyramine	Aerial part	$C_{18}H_{19}NO_4$		[28]
Organic acids	α-Linolenic acid	Leaf	$C_{18}H_{30}O_2$		[29]
	Palmitic acid	Leaf	$C_{16}H_{32}O_2$		[30]
	p-Coumaric acid	Whole plant	$C_9H_8O_3$		[25]
	Linoleic acid	Leaf	$C_{18}H_{32}O_2$		[31]
	Stearic acid		$C_{18}H_{36}O_2$		[30]
	Ferulic acid	Whole plant	$C_{10}H_{10}O_4$		[25]
	Oleic acid	Leaf	$C_{18}H_{34}O_2$		[30]








(Continued)

Table I (Continued).

Classification	Chemical component	Part of plant	Molecular Formula	Structural Formula	Reference
	Caffeic acid	Aerial part	$C_9H_8O_4$		[32]
	Oxalic acid	Leaf	$C_2H_2O_4$		[33]
Terpenoids	Lupeol	Aerial part	$C_{30}H_{50}O$		[34]
	Eleutheroside A		$C_{35}H_{60}O_6$		[15]
	Taraxerol		$C_{30}H_{50}O$		[15]
	Oleanolic acid		$C_{30}H_{48}O_3$		[15]
	Cycloartenol		$C_{30}H_{50}O$		[15]

(Continued)

Table I (Continued).

Classification	Chemical component	Part of plant	Molecular Formula	Structural Formula	Reference
Other compounds	7-Hydroxycoumarin		$C_9H_6O_3$		[18]
	Bergapten		$C_{12}H_8O_4$		[18]
	Isopimpinellin		$C_{13}H_{10}O_5$		[35]
	Scopoletin	Leaf	$C_{10}H_8O_4$		[18]
	β -Carotene		$C_{40}H_{56}$		[30]
	Melatonin	Leaf	$C_{13}H_{16}N_2O_2$		[29]
	Vitamin C	Leaf	$C_6H_8O_6$		[31]

Mechanisms of Action of POL in UC Treatment

UC has a complex pathogenesis, which is influenced by multiple risk factors, including genetic susceptibility, mucosal barrier defects, dysregulated immune response, intestinal flora dysbiosis, persistent inflammatory interactions, and environmental stress.^{1,36} Several studies have shown that POL might intervene in UC by modulating the above pathways.

POL Mediates UC Treatment by Regulating the Intestinal Flora

Several studies have found that intestinal flora dysbiosis played an important role in the pathogenesis of UC. The intestinal microbiota is a complex and rich ecosystem. Microorganisms settle in the nutrient-rich environment of the colon and provide energy and nutrients to the host, protect the host, and regulate the host's immune system.^{37–40} Feng et al⁴¹ and Zhou et al⁴² found that treatment with 0.3 mL of 0.5 g/mL *P. oleracea* polysaccharide (POP) significantly increased the abundance of intestinal *Bifidobacteria* and *Lactobacilli* and significantly decreased the abundance of Enterobacteriaceae and Enterococcus in dextran sulfate sodium (DSS)-induced UC mice. Additionally, they found that POP treatment increased the level of anti-inflammatory cytokine interleukin (IL)-10 in the intestinal mucosa and reduced endotoxin content in the peripheral blood and the levels of pro-inflammatory cytokines, tumor necrosis factor (TNF)- α , and IL-6 in UC mice. In addition, they found that POP treatment attenuated the DSS-induced colonic histopathological changes in UC mice. Ren et al⁴³ found that POL-*Cinnamomum cassia Presl* treatment significantly regulated the 5% DSS-induced Bifidobacteriaceae, *Moryella*, *Lachnospiraceae-ND-3007-group*, *Bacteroidales-BS11-gut-group*, Coriobacteriales, *Negativibacillus*, *Jeotgalicoccus*, and *Rikenellaceae-RC9-gut-group*. Moreover, intestinal flora analysis revealed that POL-*Cinnamomum cassia Presl* treatment partially restored intestinal flora structure and reduced intestinal inflammation.

Myricetin is a natural dietary flavonoid with a wide range of pharmacological activities, including antioxidant, anti-inflammatory, anticarcinogenic, and antiproliferative activities.⁴⁴ Moreover, it maintains the composition of Firmicutes and Actinomycetes in the intestinal flora. Myricetin-3-O- β -D-lactose sodium salt (M10) has been demonstrated to be highly effective in preventing DSS-induced chronic inflammation of colonic tissues and intestinal flora dysbiosis in mice.⁴⁵ Quercetin supplementation was found to inhibit *Citrobacter rodentium*-induced inflammation in mice by inhibiting pro-inflammatory cytokines, such as IL-17, TNF- α , and IL-6; increasing the abundance of *Bacteroides*, *Bifidobacterium*, *Lactobacillus*, and *Clostridium*; and significantly decreasing the abundance of *Fusobacterium* and *Enterococcus*.⁴⁶ Notably, melatonin was found to exert anti-colitis effects by recognizing bacteria through toll-like receptor (TLR)-4, regulating bacteria through adenosine monophosphate, and altering goblet cells.⁴⁷ Vitamin C supplementation was found to attenuate acute inflammation and subchronic inflammation during early recovery from colon cancer by modulating inflammatory mediators and cytokines and regulating the abundance of inflammation-associated gut bacteria.⁴⁸ However, vitamin C deficiency increased inflammatory cell infiltration and oxidative stress.⁴⁹

Elkhayat et al reported that the ethanolic extract of POL exhibited antimicrobial activity against both Gram-positive and Gram-negative bacteria.³⁴ Moreover, previous studies have shown that the ethanolic extract of POL modulated bacterial proliferation and growth, thereby down-regulating the levels of IL-1, -6, and -17; TNF- α ; interferon (IFN)- γ ; and nuclear factor kappa B (NF κ B).^{50,51} Ning et al obtained extracts of *P. oleracea* macromolecules (POEM) (>10 kDa) and small molecules (POES) (<1 kDa) by membrane separation and found that POEM contained higher protein content, while POES contained higher organic acid and alkaloid content.⁵² Additionally, they found that POEM alleviated DSS-induced UC in mice by regulating the antioxidant capacity and intestinal flora. Zhu et al found that *P. oleracea* L-derived exosome-like nanoparticles (PELNs) showed excellent stability and safety in the GI tract and exhibited affinity for the inflammation site in mice colon. Moreover, they found that oral administration of PELNs maintained intestinal flora diversity and homeostasis, enhanced the growth of *Lactobacillus reuteri*, elevated the levels of indole derivatives, activated aryl hydrocarbon receptor (AhR) in conventional CD4⁺ T cells, down-regulated *Zbtb7b* gene expression, and reprogrammed the conversion of conventional CD4⁺ T cells into double-positive CD4⁺CD8⁺ T cells (Figure 2A).⁵³

POL Mediates UC Treatment by Repairing the Mucosal Barrier

The intestinal mucosal barrier is composed of intestinal mucosal epithelium, intestinal mucus, intestinal flora, secretory immunoglobulins (sIg), and intestine-associated lymphoid tissues, including biological, chemical, mechanical, and immune barriers.⁵⁴ The four barriers maintain the stability of intestinal mucosal barrier function (MBF) and the integrity




Figure 2 (A) *P. oleracea* L. alleviates intestinal inflammation by regulating gut microbiota in mice. (B) *P. oleracea* L. alleviates ulcerative colitis (UC) by repairing the mucosal barrier. (C) The active components of *P. oleracea* L., including quercetin, β -carotene, and Oleracein E, alleviate UC by regulating the inflammatory response and immune system through related signaling pathways. (D) *P. oleracea* L. alleviates UC by regulating apoptosis, autophagy, endoplasmic reticulum stress, and other pathways.

of intestinal mucosa by effectively identifying and eliminating harmful substances both inside and outside the intestines. Impaired intestinal MBF is considered to play a central role in the development and progression of UC.⁵⁵ Apigenin (API), a POL flavonoid, ameliorates DSS-induced murine experimental colitis by inhibiting canonical and non-canonical inflammasome signaling pathways.⁵⁶ Additionally, a study found that API-Mn(II) loaded sodium hyaluronate nanoparticles (prepared by incorporating API in Mn^{2+} framework and subsequently coated with hyaluronic acid) significantly improved the damaged colonic tissues and repaired the intestinal barrier by mediating inflammatory factors, attenuating the damage to tight junctions, increasing cellular density, and narrowing cellular gaps.⁵⁷ M10, prevents DSS-induced UC by inhibiting colonic mucosal cell necrosis and remodeling the intestinal barrier.⁵⁸ Dai et al found that POP increased the sIg-A content of intestinal mucosa, improved colonic histopathological changes, and exerted therapeutic effects against DSS-induced UC in mice.⁵⁹ Additionally, POP exerts therapeutic effects against UC by reducing the expression of caspase-3 and caspase-8 in colonic epithelial cells, regulating epithelial cell apoptosis, and promoting mucosal repair.⁶⁰ Ning et al found that POP maintained intestinal retinol and short-chain fatty acid levels, promoted colonic B-cell proliferation and differentiation, and increased intestinal IgA expression, thereby improving the intestinal barrier and maintaining intestinal homeostasis.⁶¹ Finally, purslane juice was found to improve DSS-induced UC by decreasing the expression of NOD-like receptor protein 3 inflammasomes to inhibit cellular pyroptosis and by up-regulating the expression of tight junction proteins to repair intestinal barrier dysfunction (Figure 2B).⁶²

POL Mediates UC Treatment by Regulating the Immune Response

Studies on the immune response and inflammatory pathways in UC have shown that the imbalance between pro-inflammatory and anti-inflammatory cytokines mediated UC development. The induction of C-reactive proteins, IFN- γ , lipopolysaccharide (LPS), and TNF- α can induce M1 polarization of macrophages during the active phase of a disease.⁶³ The M1 macrophages release pro-inflammatory cytokines and chemokines, such as IL-1, IL-6, IL-8, IL-18, IL-

12, IL-23, IFN- γ , inducible nitric oxide synthase, and reactive oxygen intermediates, which participate in acute inflammatory responses and disrupt the intestinal mucosal barrier, as well as mediate cellular immunity and intervene in disease prognosis.^{64,65} During intestinal injury, large amounts of neutrophils are rapidly recruited to the site of injury, where they trigger the recruitment of other immune cells, consequently generating an over-immune response, which is associated with the aggravation of intestinal inflammation and mucosal damage in the early stages of UC.^{66,67} In contrast, macrophage polarization leads to the accumulation and release of various pro-inflammatory factors or regulatory anti-inflammatory cytokines in the local intestinal segments of IBD lesions to exert biological effects.⁶⁸ Studies have shown that M2 macrophages primarily secrete anti-inflammatory factors, such as IL-10, transforming growth factor- β , and arginase 1, which induced Th2-type immune response, suppressed inflammatory response, and promoted tissue repair and tumor progression.⁶⁵

Several studies have shown that the active ingredients of POL could play a preventive and therapeutic role against the onset, development, drug resistance, and other related processes of UC by modulating the inflammatory response and the immune system (Figure 2C). Studies have found that quercetin, which was abundant in POL, could inhibit LPS-induced production of IL-6, TNF- α , and IL-8, thus exerting an anti-inflammatory effect.⁶⁹ Additionally, a study found that quercetin treatment partially restored DSS-induced loss of epithelial integrity in C57BL/6 mice by inducing tight junction proteins via AhR-mediated anti-inflammatory mechanisms. Moreover, quercetin restores innate and adaptive intestinal immune system homeostasis by down-regulating neutrophil and macrophage activity and by shifting the Th17/ T-cell (Treg) ratio in favour of the Treg subpopulation, respectively.⁷⁰ Meanwhile, β -carotene exhibits anti-inflammatory functions by inhibiting LPS-induced secretion of macrophage inflammatory factors, such as IL-1 β , IL-6, and TNF- α , via down-regulating the expression of NF- κ B p65 protein in the NF- κ B pathway.⁷¹ Myricetin exerts anti-inflammatory effects in UC mice by increasing Treg proliferation, decreasing Th1 and Th17 cell proliferation, and promoting immune cell homeostasis.⁷² Huang et al demonstrated that Oleracein E (OE) significantly increased catalase activity, decreased myeloperoxidase (MPO) activity, and decreased IL-1 β , IL-6, and TNF- α levels in LPS-induced Caco-2 cells and 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced UC rats.⁷³ In addition, OE may reduce the level of oxidative stress by activating the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 pathway, thereby improving intestinal mucosal barrier damage. Previous studies have found that genistein and lupeol mediated the anti-inflammatory effects against IBD by promoting M1 to M2 polarization of macrophages. Intriguingly, lupeol promotes M1 to M2 polarization of infiltrating macrophages by inhibiting IRF5 and possibly other transcription factors critical for M1-type polarization via a specific receptor and down-stream signaling pathways, such as p38 MAPK.^{74,75} In addition, genistein flavonoids reduce serum cytokine expression levels, reduce MPO activity, and significantly down-regulate COX-2 protein expression levels in TNBS-induced UC rats.⁷⁶ Zhou et al found that POL might mediate its therapeutic effects against UC by restoring Th1 and Th2 homeostasis, which further led to a significant decrease in IFN- γ expression and a significant increase in IL-10 expression in the colon of TNBS-induced UC rats.⁷⁷ Vanden Braber et al found that microencapsulated genistein significantly attenuated intestinal inflammation and tissue damage in mice and restored the expression of IL-10, which was a key factor in mucosal homeostasis.⁷⁸

Among the immunomodulatory factors, oxidative stress is considered to be one of the main mechanisms associated with the pathophysiology of IBD.⁷⁹ Studies have found that chronic intestinal inflammation was associated with the overproduction of reactive oxygen and nitrogen species.⁸⁰ Induced oxidative stress injury disrupts intracellular homeostasis, which may lead to intestinal flora disorders, dysregulated immune response, altered MBF, abnormal autophagy, and intestinal fibrosis, thus further exacerbating intestinal inflammation.^{81,82} Quercetin, a constituent of POL, protects against indomethacin-induced oxidative stress and GI inflammation through its antioxidant and anti-inflammatory properties.⁸³ Luteolin significantly attenuates disease activity index colon shortening, and histological damage in DSS-induced UC mice by activating Nrf2-mediated antioxidant activity.⁸⁴

A few studies found that POPs could regulate TNF- α /NF- κ B and IL-6/signal transducer and activator of transcription 3 (STAT3) signaling pathways and reduce soluble IL-6 receptor-alpha (sIL-6R α) and glycoprotein 130 levels, as well as colonic MPO and NF- κ B levels in rats. Additionally, POPs can attenuate sIL-6R α -IL-6-induced inflammatory responses; inhibit p-STAT3, COX-2, and ikB-alpha expression; and inhibit CXC chemokine ligand 1 and its receptor CXC chemokine receptor 2, thereby decreasing neutrophil recruitment to the inflammatory sites and reducing UC

symptoms.^{85–88} Ai et al found that API inhibited inflammation and inflammation-induced carcinogenesis under normal conditions by regulating the STAT3/NF- κ B signaling pathway.⁸⁹

Bian Yifei found that the aqueous POL extract played an anti-inflammatory role by inhibiting the expression of inflammatory factors, such as TNF- α , IL-1 β , and IL-6, and TLR4/NF κ B pathway proteins. In addition, quercetin and cannabiniol, the active ingredients of POL, inhibit the expression of TLR4/NF κ B/MAPK/STAT pathway proteins in LPS-induced rat microvascular endothelial cells.⁹⁰

A study reported that IL-17 levels in peripheral blood monocytes were associated with the severity of IBD.⁹¹ By using cyberpharmacological analysis, Chen et al found that combination treatment with pannotoginseng and purslane regulated the IL-17, TNF, and proteoglycan signaling pathways and exerted a preventive effect against the onset, progression, and resistance of UC.⁹²

Other Mechanisms of Action of POL in UC Treatment

Studies have found that the active components in POL exhibited anti-inflammatory effects by reducing the release of inflammatory transmitters, such as TNF- α , by inhibiting MAPK.^{93,94} Zhang et al used network pharmacology to screen 10 active ingredients of POL, including arachidonic acid, β -sitosterol, kaempferol, luteolin, isobetaine, and quercetin, and found 62 core targets, which were closely associated with cancer, viral infection, IBD, and immune regulation. Additionally, the study found that 17 of core targets played a multi-targeted, multi-pathway role in alleviating UC through anti-inflammatory, antioxidant, and cell proliferation and apoptosis regulation, including multidrug resistance-associated protein 4, serum albumin, IFN gamma, inhibitor of NF κ B kinase subunit alpha, MPO, nitric oxide synthase, inducible, nuclear receptor subfamily 1 group I member 2, peroxisome proliferator-activated receptor gamma, TNF, xanthine dehydrogenase/oxidase.⁹⁵ Yang et al found that POP mediated UC treatment by regulating the TLR4/MyD88/NF- κ B signaling pathway in DSS-induced UC mice.⁹⁴

In experiments, some active ingredients of POL were found to be associated with the MAPK signaling pathway and important inflammatory transmitters, such as TNF, IL-1 β , IL-4, and IL-6. Additionally, the anti-inflammatory effects of POL components, such as 1-carbomethoxy- β -carboline, luteolin, kaempferol, quercitrin, and cis-N-feruloyl-3'-methoxytyramine, were also confirmed in these studies.^{96–99} Ma et al suggested that POL might mediate its therapeutic effects in UC by regulating the mTOR signaling pathway based on network pharmacology analysis.⁹ The mTOR is a serine/threonine protein kinase consisting of mTORC1 complexes and mTORC2 complexes. The mTORC1 and mTORC2 complexes form a signaling pathway with other proteins, respectively, to regulate cell growth, proliferation, and survival, as well as organismal growth and internal homeostasis based on external signals.¹⁰⁰ Additionally, the mTOR signaling pathway participates in autophagy, which is essential for UC pathogenesis.

Numerous studies have indicated that endoplasmic reticulum stress (ERS)-induced autophagy synergistically promoted UC pathogenesis by targeting intestinal epithelial cells (IECs).¹⁰¹ A study found that POL extracts attenuated ERS-induced autophagy of IECs through the protein kinase R-like endoplasmic reticulum kinase/eukaryotic initiation factor 2 α /Beclin1/microtubule-associated protein light chain 3II pathway, thereby mediating its therapeutic effects in UC.¹⁰² M10 significantly increases the number of CD8⁺ and CD4⁺ T lymphocytes and reduces macrophage phagocytosis, thereby attenuating ERS-induced autophagy and apoptosis and preventing chronic inflammation and colorectal tumorigenesis.¹⁰³ Melatonin slows the progression of UC-associated colorectal cancer by modulating autophagy and Nrf2 signaling pathways.¹⁰⁴ Another study found that POL extract alleviated UC in mice by modulating inflammatory response, apoptosis, and PPAR- γ levels (Figure 2D).^{105,106}

Clinical Studies of POL in UC Treatment

POL Monotherapy

Liu et al found that treatment with POL capsules (n = 6, 0.35 g/capsule, tid po) and traditional Chinese herbal colitis enema solution rapidly alleviated clinical UC symptoms, repaired colonic mucosa, and reduced inflammatory response, without any adverse reactions.^{107–109} Clinical observations revealed that this combination treatment was safer and more effective than Sulfasalazine Tablets (91.42% vs 76.47%).¹⁰⁷

POL Compounds

Clinical studies have found that the combination of compound POL decoction (containing *POL* 150 g, *Granatum* 100 g, *Elaeagnus angustifolia* Linn. 300 g, *Cichorium intybus* L. 20 g, etc.) and compound *Rhizoma coptidis* decoction could obtain ideal therapeutic effects in the treatment of colitis, especially when consumed in the earlier stages of UC.¹¹⁰ Wang et al found that a self-made POL decoction (containing *POL* 30 g, *Sargentodoxa cuneata* (Oliv). Rehd. and E. H. Wilson in C. S. Sargent 20 g, *Taraxacum mongolicum* Hand.-Mazz. 10 g, *Fraxini Cortex* 10 g, etc.) showed a cure rate of 80.5% and a total effective rate of 95.1% when used as the primary treatment for 41 UC cases.¹¹¹ These results suggest that this formula is simple and easy to implement and is reliable for the treatment of mild and moderate chronic UC, with a low rate of recurrence. Pan et al found that a POL decoction, POL as a sovereign medicine (containing *POL* 30 g, *Hedyotis diffusa* 20 g, *Codonopsis Radix* 12 g, *Poria* 10 g, *Atractylodes macrocephala* 10 g, etc.) internal and POL enema showed a total effective rate of 93.75% when used to treat 32 UC cases.¹¹² A clinical study found that treatment with POL enema alone showed a total effective rate of 84.21% in 38 UC cases.¹¹³ Another study found that Jingfang and Purslane decoction (containing *POL* 30 g, *Gentianae Macrophyllae Radix* 30 g, *Nepeta cataria* L. 15 g, and *Saposhnikoviae Radix* 15 g) showed a total effective rate of 95.7% in 68 UC cases, suggesting that this prescription improves intestinal function and has immunoregulatory and antibacterial effects.¹¹⁴

However, the existing clinical studies on POL monotherapy and its combination therapy in the treatment of UC are small-scale, single-center studies. Therefore, more standardized, scientific, and rigorous clinical trials are needed to provide evidence-based reports on the role of POL in UC treatment. In addition, previous studies have indicated that POL had a certain degree of nephrotoxicity, making it necessary to standardize its optimal dosage in clinical applications.¹¹⁵

Conclusion

POL has a long history of use as food and medicine, and it shows significant efficacy in the treatment of UC. In addition to inhibiting IEC apoptosis, POL inhibits the release of inflammatory factors and promotes colonic mucosal repair in UC rats. TCM POL effectively improves the pathological state of intestinal mucosa in UC patients, thereby relieving their clinical symptoms and promoting mucosal healing. This review summarizes the mechanisms of action and clinical research progress of *P. oleracea* L. in the treatment of UC, indicating the novel targets and more effective treatment modalities for UC. Despite these promising findings, further research is essential to optimize POL's clinical application. As a herbal medicine, POL is a chemical entity formed by the polymerization of multiple components, but the active ingredients or active molecular groups of various herbs have not been clearly defined, the interactions between various components in herbal medicines are not clear, and its toxic effects are of concern. In addition, clinical data describing the mode of action of the naturally active compounds of POL are still lacking. Therefore, long-term clinical studies assessing the safety and efficacy of POL as a potential treatment against UC remain necessary.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

This study was funded by the grants from the National Natural Science Foundation of China, No. 81873253; the Shanghai Natural Science Foundation, No. 22ZR1458800; the scientific research Project Plan of Shanghai Municipal Health Commission, No. 202240385; the XingLin Scholar Program of Shanghai University of Traditional Chinese Medicine, No. [2020]23; and the Science and Technology Innovation Cultivation Program of LongHua, No. YD202220.

Disclosure

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

1. Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. *Lancet*. 2023;402(10401):571–584. doi:10.1016/s0140-6736(23)00966-2
2. Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. *Mayo Clin Proc*. 2019;94(7):1357–1373. doi:10.1016/j.mayocp.2019.01.018
3. Du L, Ha C. Epidemiology and pathogenesis of ulcerative colitis. *Gastroenterol Clin North Am*. 2020;49(4):643–654. doi:10.1016/j.gtc.2020.07.005
4. Wei SC, Sollano J, Hui YT, et al. Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia. *Expert Rev Gastroenterol Hepatol*. 2021;15(3):275–289. doi:10.1080/17474124.2021.1840976
5. Gros B, Kaplan GG. Ulcerative colitis in adults: a review. *JAMA*. 2023;330(10):951–965. doi:10.1001/jama.2023.15389
6. Wu K, Chen M, Qian J, Inflammatory Bowel Disease Group CSOG, Chinese Medical Association, China IBDQCCo. Chinese clinical practice guideline on the management of ulcerative colitis (2023, Xi'an). *Chin J Inflamm Bowel Dis*. 2024;01:33–58. doi:10.3760/cma.j.cn101480-20240123-00017.
7. Medicine CAo I. Experts consensus on diagnosis and treatment of ulcerative colitis by integrative medicine. *Chinese Journal of Integrated Traditional and Western Medicine*. 2023;43(01):5–11.
8. Zhang S, Zhao L, Shen H, et al. International clinical practice guideline on the use of traditional Chinese medicine for ulcerative colitis by Board of Specialty Committee of Digestive System Disease of World Federation of Chinese Medicine Societies (2023). *Phytother Res*. 2024;38(2):970–999. doi:10.1002/ptr.8087
9. Ma X, Du X, Wang X, et al. Mechanism of machixian (portulacae herba) on ulcerative colitis based on network pharmacology. *Shandong J Tradition Chin Med*. 2020;39(11):1240–1247. doi:10.16295/j.cnki.0257-358x.2020.11.020
10. Li K, Xia T, Jiang Y, et al. A review on ethnopharmacology, phytochemistry, pharmacology and potential uses of *Portulaca oleracea* L. *J Ethnopharmacol*. 2024;319(Pt 2):117211. doi:10.1016/j.jep.2023.117211
11. Kumar A, Sreedharan S, Kashyap AK, Singh P, Ramchiary N. A review on bioactive phytochemicals and ethnopharmacological potential of purslane (*Portulaca oleracea* L.). *Heliyon*. 2022;8(1):e08669. doi:10.1016/j.heliyon.2021.e08669
12. Rahimi VB, Ajam F, Rakhshandeh H, Askari VR. A pharmacological review on portulaca oleracea L.: focusing on anti-inflammatory, anti-oxidant, immuno-modulatory and antitumor activities. *J Pharmacopuncture*. 2019;22(1):7–15. doi:10.3831/kpi.2019.22.001
13. Jalali J, Ghasemzadeh Rahbardar M. Ameliorative effects of *Portulaca oleracea* L. (purslane) on the metabolic syndrome: a review. *J Ethnopharmacol*. 2022;299:115672. doi:10.1016/j.jep.2022.115672
14. Iranshahy M, Javadi B, Iranshahi M, et al. A review of traditional uses, phytochemistry and pharmacology of *Portulaca oleracea* L. *J Ethnopharmacol*. 2017;205:158–172. doi:10.1016/j.jep.2017.05.004
15. Wu X, Gao S. Research progress on active components and pharmacological effects of purslane. *J Anhui Agric Sci*. 2023;51(10):21–24.
16. Li K. Research progress on flavonoids and alkaloids in portulaca oleracea L. *Pharm Inform*. 2023;12(04):317–337. doi:10.12677/pi.2023.124040
17. Ghorani V, Saadat S, Khazdair MR, Gholamnezhad Z, El-Seedi H, Boskabady MH. Phytochemical characteristics and anti-inflammatory, immunoregulatory, and antioxidant effects of portulaca oleracea L.: a comprehensive review. *Evid Based Complement Alternat Med*. 2023;2023(1):2075444. doi:10.1155/2023/2075444
18. Wang T, Liu Y, Xiao F, et al. Chemical composition and pharmacological activity of portulaca olerace. *Chin J Exp Traditional Med Formulae*. 2018;24(06):224–234. doi:10.13422/j.cnki.syfjx.20180671
19. Dias MG, Camões MFGFC, Oliveira L. Carotenoids in traditional Portuguese fruits and vegetables. *Food Chem*. 2009;113(3):808–815. doi:10.1016/j.foodchem.2008.08.002
20. Xu X, Yu L, Chen G. Determination of flavonoids in *Portulaca oleracea* L. by capillary electrophoresis with electrochemical detection. *J Pharmaceutical & Biomed Analysis*. 2006;41(2):493–499. doi:10.1016/j.jpba.2006.01.013
21. Zhang S, Qiu S, Huang H, et al. Transcriptome and metabolome analyses of flavonoids metabolism in leaf, stem and root of *Portulaca oleracea* L. *Acta Botanica Boreali-Occidentalia Sinica*. 2021;41(02):254–261.
22. Zhu H, Wang Y, Liu Y, Xia Y, Tang T. Analysis of flavonoids in portulaca oleracea L. by UV–Vis spectrophotometry with comparative study on different extraction technologies. *Food Anal Methods*. 2010;3(2):90–97. doi:10.1007/s12161-009-9091-2
23. Chen J, Shi Y-P, Liu J-Y. Determination of noradrenaline and dopamine in Chinese herbal extracts from *Portulaca oleracea* L. by high-performance liquid chromatography. *J Chromatogr A*. 2003;1003(1–2):127–132. doi:10.1016/s0021-9673(03)00786-6
24. Yue ME, Jiang TF, Shi YP. Simultaneous determination of noradrenaline and dopamine in *Portulaca oleracea* L. by capillary zone electrophoresis. *J Separation Sci*. 2005;28(4):360–364. doi:10.1002/jssc.200400045
25. Xiang L, Xing D, Wang W, Wang R, Ding Y, Du L. Alkaloids from *Portulaca oleracea* L. *Phytochemistry*. 2005;66(21):2595–2601. doi:10.1016/j.phytochem.2005.08.011
26. Yan J, Sun L-R, Zhou Z-Y, et al. Homoisoflavonoids from the medicinal plant *Portulaca oleracea*. *Phytochemistry*. 2012;80:37–41. doi:10.1016/j.phytochem.2012.05.014
27. Liu Z, Wang Z, Zhang X, et al. Recent advances in research on chemical components and antibacterial activities of *Portulaca oleracea* L. *Food Sci*. 2023;359–371.
28. Tian JL, Liang X, Gao PY, et al. Two new alkaloids from *Portulaca oleracea* and their cytotoxic activities. *J Asian Nat Prod Res*. 2014;16(3):259–264. doi:10.1080/10286020.2013.866948
29. Simopoulos AP, Tan D-X, Manchester LC, Reiter RJ. Purslane: a plant source of omega-3 fatty acids and melatonin. *J Pineal Res*. 2005;39(3):331–332. doi:10.1111/j.1600-079X.2005.00269.x
30. Palaniswamy UR, McAvoy RJ, Bible BB. Stage of Harvest and Polyunsaturated Essential Fatty Acid Concentrations in Purslane (*Portulaca oleracea*) Leaves. *Journal of Agricultural and Food Chemistry*. 2001;49(7):3490–3493. doi:10.1021/jf0102113
31. Uddin MK, Juraimi AS, Hossain MS, Nahar MAU, Ali ME, Rahman MM. Purslane weed (*Portulaca oleracea*): a prospective plant source of nutrition, omega-3 fatty acid, and antioxidant attributes. *Sci World J*. 2014;2014:951019. doi:10.1155/2014/951019
32. Yang Z, Liu C, Xiang L, Zheng Y. Phenolic alkaloids as a new class of antioxidants in *Portulaca oleracea*. *Phytother Res*. 2009;23(7):1032–1035. doi:10.1002/ptr.2742
33. Palaniswamy U, Bible B, McAvoy R. Effect of nitrate: ammonium nitrogen ratio on oxalate levels of purslane. *Trends in New Crops and New Uses*. 2002;11:453–455.

34. Elkhayat ES, Ibrahim SRM, Aziz MA. Portulene, a new diterpene from *Portulaca oleracea* L. *J Asian Nat Prod Res.* 2008;10(11):1039–1043. doi:10.1080/10286020802320590
35. Aljeboori KH, AL-Rubai OHK, Yassen Y. Study of pathological, effects of crude extract of *Portulaca oleracea* L. in the albino mice organs. *Pharmacol Res Modern Chin Med.* 2014;4:100101.
36. Cao Z, Zhou X. Ulcerative colitis and intestinal microecology. 2018;1.
37. Witkowski M, Weeks TL, Hazen SL. Gut microbiota and cardiovascular disease. *Circ Res.* 2020;127(4):553–570. doi:10.1161/circresaha.120.316242
38. Chen Y, Michalak M, Agellon LB. Importance of nutrients and nutrient metabolism on human health. *Yale J Biol Med.* 2018;91(2):95–103.
39. Leslie JL, Vendrov KC, Jenior ML, Young VB. The gut microbiota is associated with clearance of clostridium difficile infection independent of adaptive immunity. *mSphere.* 2019;4(1). doi:10.1128/mSphereDirect.00698-18
40. Sefik E, Geva-Zatorsky N, Oh S, et al. MUCOSAL IMMUNOLOGY. Individual intestinal symbionts induce a distinct population of ROR γ regulatory T cells. *Science.* 2015;349(6251):993–997. doi:10.1126/science.aaa9420
41. Feng L, Li S, Dai L, et al. Effects of polysaccharides from *Portulaca* L. on intestinal mucosal cytokines and intestinal flora in mice with ulcerative colitis. *Chin J Microecol.* 2015;27(02):139–142. doi:10.13381/j.cnki.cjm.201502004
42. Zhou Z, Ma T, Feng L, et al. Effects of polysaccharides from *Portulaca Oleracea* L. on intestinal flora and blood endotoxin in mice with ulcerative colitis. *Chin J Microecol.* 2014;26(06):646–648. doi:10.13381/j.cnki.cjm.201406006
43. Ren L, Tang Z, Liang Y, et al. Preparation of *Portulacae herba-cinnamomi cortex granules* and its effect on intestinal flora of ulcerative colitis mice. *Chin J Microecol.* 2019;31(02):130–137. doi:10.13381/j.cnki.cjm.201902002
44. Zhu S, Yang C, Zhang L, et al. Development of M10, myricetin-3-O- β -D-lactose sodium salt, a derivative of myricetin as a potent agent of anti-chronic colonic inflammation. *Eur J Med Chem.* 2019;174:9–15. doi:10.1016/j.ejmech.2019.04.031
45. Miao RR, Zhan S, Hu XT, et al. Myricetin and M10, a myricetin-3-O- β -D-lactose sodium salt, modify composition of gut microbiota in mice with ulcerative colitis. *Toxicol Lett.* 2021;346:7–15. doi:10.1016/j.toxlet.2021.03.009
46. Lin R, Piao M, Song Y. Dietary quercetin increases colonic microbial diversity and attenuates colitis severity in *Citrobacter rodentium*-infected mice. *Front Microbiol.* 2019;10:1092. doi:10.3389/fmicb.2019.01092
47. Kim SW, Kim S, Son M, Cheon JH, Park YS. Melatonin controls microbiota in colitis by goblet cell differentiation and antimicrobial peptide production through Toll-like receptor 4 signalling. *Sci Rep.* 2020;10(1):2232. doi:10.1038/s41598-020-59314-7
48. Jeon HJ, Yeom Y, Kim YS, et al. Effect of vitamin C on azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated early colon cancer in mice. *Nutr Res Pract.* 2018;12(2):101–109. doi:10.4162/nrp.2018.12.2.101
49. Jo H, Lee D, Go C, et al. Preventive effect of vitamin C on Dextran Sulfate Sodium (DSS)-induced colitis via the regulation of IL-22 and IL-6 Production in Gulo(-/-) Mice. *Int J Mol Sci.* 2022;23(18):10612. doi:10.3390/ijms231810612
50. Alfvuaires MA, Algefare AI, Afkar E, Salam SA, El-Moaty HIA, Badr GM. Immunomodulatory assessment of *Portulaca oleracea* L. extract in a mouse model of colitis. *Biomed Pharmacother.* 2021;143:112148. doi:10.1016/j.biopha.2021.112148
51. Peng C, Ouyang Y, Lu N, Li N. The NF- κ B signaling pathway, the microbiota, and gastrointestinal tumorigenesis: recent advances. *Front Immunol.* 2020;11:1387. doi:10.3389/fimmu.2020.01387
52. Ning K, Duan Y, Tong W, et al. Protective effects of different molecular weights of purslane (*Portulaca oleracea* L.) aqueous extract on DSS-induced ulcerative colitis in mice. *Antioxidants.* 2023;12(7). doi:10.3390/antiox12071400
53. Zhu MZ, Xu HM, Liang YJ, et al. Edible exosome-like nanoparticles from *portulaca oleracea* L. mitigate DSS-induced colitis via facilitating double-positive CD4(+)CD8(+)T cells expansion. *J Nanobiotechnology.* 2023;21(1):309. doi:10.1186/s12951-023-02065-0
54. Wang K, Wu LY, Dou CZ, Guan X, Wu HG, Liu HR. Research advance in intestinal mucosal barrier and pathogenesis of Crohn's disease. *Gastroenterol Res Pract.* 2016;2016:9686238. doi:10.1155/2016/9686238
55. Huang WC, Liang J, Nagahashi M, et al. Sphingosine-1-phosphate phosphatase 2 promotes disruption of mucosal integrity, and contributes to ulcerative colitis in mice and humans. *FASEB j.* 2016;30(8):2945–2958. doi:10.1096/fj.201600394R
56. Márquez-Flores YK, Villegas I, Cárdeno A, Rosillo M, Alarcón-de-la-Lastra C. Apigenin supplementation protects the development of dextran sulfate sodium-induced murine experimental colitis by inhibiting canonical and non-canonical inflammasome signaling pathways. *J Nutr Biochem.* 2016;30:143–152. doi:10.1016/j.jnutbio.2015.12.002
57. Lv F, Zhang Y, Peng Q, et al. Apigenin-Mn(II) loaded hyaluronic acid nanoparticles for ulcerative colitis therapy in mice. *Front Chem.* 2022;10:969962. doi:10.3389/fchem.2022.969962
58. Zhou XL, Yang J, Qu XJ, Meng J, Miao RR, Cui SX. M10, a myricetin-3-O- β -D-lactose sodium salt, prevents ulcerative colitis through inhibiting necroptosis in mice. *Front Pharmacol.* 2020;11:557312. doi:10.3389/fphar.2020.557312
59. Dai Y, Han Z, Yang C, et al. Effects of polysaccharides from *Portulaca oleracea* L. on intestinal mucosal slgA and pathological manifestations in mice ulcerative colitis. *Chin J Microecol.* 2016;28(08):903–905+915. doi:10.13381/j.cnki.cjm.201608008
60. Pan F, Zhang T, Chen J. The POP interfered with the expression of caspase-3 and caspase-8 in a rat experimental model of TNBS-induced colitis. *Chin Archiv Tradition Chin.* 2010;28(08):1639–1641. doi:10.13193/j.archctm.2010.08.73.panf.074
61. Ning K, Shi C, Chi YY, et al. *Portulaca oleracea* L. polysaccharide alleviates dextran sulfate sodium-induced ulcerative colitis by regulating intestinal homeostasis. *Int J Biol Macromol.* 2024;256(Pt 2):128375. doi:10.1016/j.ijbiomac.2023.128375
62. Fan YM, Wei YY, Wang HR, Yu G, Zhang YN, Hao Z. Inhibitory effect of *Portulaca oleracea* L. aqueous extract and juice on NLRP3 inflammasome activation in an ulcerative colitis mouse model. *Environ Sci Pollut Res Int.* 2023;30(36):86380–86394. doi:10.1007/s11356-023-28365-4
63. Arnold CE, Whyte CS, Gordon P, Barker RN, Rees AJ, Wilson HM. A critical role for suppressor of cytokine signalling 3 in promoting M1 macrophage activation and function in vitro and in vivo. *Immunology.* 2014;141(1):96–110. doi:10.1111/imm.12173
64. Zhang J, Zhang F, Yu X, Wang X, Li Y. Pathogenesis of ulcerative colitis and research progress of traditional Chinese and Western medicine. *J Liaoning Univ Traditional Chin Med.* 2021;23(01):70–74. doi:10.13194/j.issn.1673-842x.2021.01.017
65. Wang D, Wang H, Zhou Y, Fan H, Wang Z. Research progress of the role of macrophage polarization in inflammatory diseases. *Chin Med.* 2017;12(9):4.
66. Wu X, Liu Z. Recent advances in the pathogenesis of ulcerative colitis. *Chin J Integrated Tradition Western Med Digestion.* 2023;31(04):237–242.

67. Chen H, Wu X, Xu C, Lin J, Liu Z. Dichotomous roles of neutrophils in modulating pathogenic and repair processes of inflammatory bowel diseases. *Precis Clin Med.* 2021;4(4):246–257. doi:10.1093/pcmedi/pbab025
68. Lissner D, Schumann M, Batra A, et al. Monocyte and M1 macrophage-induced barrier defect contributes to chronic intestinal inflammation in IBD. *Inflamm Bowel Dis.* 2015;21(6):1297–1305. doi:10.1097/mib.0000000000000384
69. Geraets L, Moonen HJ, Brauers K, Wouters EF, Bast A, Hageman GJ. Dietary flavones and flavonoles are inhibitors of poly(ADP-ribose) polymerase-1 in pulmonary epithelial cells. *J Nutr.* 2007;137(10):2190–2195. doi:10.1093/jn/137.10.2190
70. Riemschneider S, Hoffmann M, Slanina U, Weber K, Hauschildt S, Lehmann J. Indol-3-carbinol and quercetin ameliorate chronic DSS-induced colitis in C57BL/6 mice by AhR-mediated anti-inflammatory mechanisms. *Int J Environ Res Public Health.* 2021;18(5):2262. doi:10.3390/ijerph18052262
71. Zhang X, Zhang S, Wu M, Ji Y, Huang Y, Zheng X. Effects and mechanism of β -carotene on inflammatory factors LPS-induced RAW264.7 cells. *Chin J Immunol.* 2017;33(06):838–843.
72. Qu X, Li Q, Song Y, et al. Potential of myricetin to restore the immune balance in dextran sulfate sodium-induced acute murine ulcerative colitis. *J Pharm Pharmacol.* 2020;72(1):92–100. doi:10.1111/jphp.13197
73. Huang Y, Su Y, Qin R, et al. Mechanism by which oleracein E alleviates TNBS-induced ulcerative colitis. *Eur J Gastroenterol Hepatol.* 2023;35(8):854–864. doi:10.1097/meg.0000000000002597
74. Abron JD, Singh NP, Price RL, Nagarkatti M, Nagarkatti PS, Singh UP. Genistein induces macrophage polarization and systemic cytokine to ameliorate experimental colitis. *PLoS One.* 2018;13(7):e0199631. doi:10.1371/journal.pone.0199631
75. Zhu Y, Li X, Chen J, et al. The pentacyclic triterpene Lupeol switches M1 macrophages to M2 and ameliorates experimental inflammatory bowel disease. *Int Immunopharmacol.* 2016;30:74–84. doi:10.1016/j.intimp.2015.11.031
76. Seibel J, Molzberger AF, Hertrampf T, Laudenbach-Leschowski U, Diel P. Oral treatment with genistein reduces the expression of molecular and biochemical markers of inflammation in a rat model of chronic TNBS-induced colitis. *Eur J Nutr.* 2009;48(4):213–220. doi:10.1007/s00394-009-0004-3
77. Zhou Y, Luo J, Zhang G, Zhang G, Zhang C. Effects of *Portulaca oleracea* L on expression of IFN- γ and IL-10 cytokine in rats with experimental colitis. *Chin Pharmacol Bulletin.* 2008;08:1113–1114.
78. Vanden Braber NL, Novotny Nuñez I, Bohl L, et al. Soy genistein administered in soluble chitosan microcapsules maintains antioxidant activity and limits intestinal inflammation. *J Nutr Biochem.* 2018;62:50–58. doi:10.1016/j.jnutbio.2018.08.009
79. Borody T, Campbell J, Torres M, Nowak A, Leis S. Reversal of Idiopathic Thrombocytopenic Purpura [ITP] with Fecal Microbiota Transplantation [FMT]: 941. *Official J Am Col Gastroenterol | ACG.* 2011;106:S352.
80. Wendland BE, Aghdassi E, Tam C, et al. Lipid peroxidation and plasma antioxidant micronutrients in Crohn disease. *Am J Clin Nutr.* 2001;74(2):259–264. doi:10.1093/ajcn/74.2.259
81. Guan G, Lan S. Implications of antioxidant systems in inflammatory bowel disease. *Biomed Res Int.* 2018;2018:1290179. doi:10.1155/2018/1290179
82. Gao Q. Oxidative stress and autophagy. *Adv Exp Med Biol.* 2019;1206:179–198. doi:10.1007/978-981-15-0602-4_9
83. Carrasco-Pozo C, Castillo RL, Beltrán C, Miranda A, Fuentes J, Gotteland M. Molecular mechanisms of gastrointestinal protection by quercetin against indomethacin-induced damage: role of NF- κ B and Nrf2. *J Nutr Biochem.* 2016;27:289–298. doi:10.1016/j.jnutbio.2015.09.016
84. Li Y, Shen L, Luo H. Luteolin ameliorates dextran sulfate sodium-induced colitis in mice possibly through activation of the Nrf2 signaling pathway. *Int Immunopharmacol.* 2016;40:24–31. doi:10.1016/j.intimp.2016.08.020
85. Wang L. *Extraction and Isolation of Polysaccharide from Portulaca Oleracea and Evaluation of Its Therapeutic Effect On Ulcerative Colitis and Its Mechanisms.* Master. Shaanxi University of Chinese Medicine; 2017.
86. Zhang T, Shi B, Chen J, Pan F. Effects of polysaccharide from *Portulaca oleracea* on the expression of CINC-1 and its receptor CXCR2 in rats ulcerative colitis. *Chinese Traditional Patent Med.* 2009;31(12):1929–1932.
87. Fan W, Wang P, Wang Q. Effects of purslane polysaccharide on the intestinal tissue IL-6/STAT3 and NF- κ B of ulcerative colitis. *Chin J Appl Physiol.* 2018;34(03):263–267.
88. Wang Z, Liang Y, Zhang D, et al. Protective effects of polysaccharide extracted from *Portulacae oleracea* L. on colitis induced by dextran sulfate sodium. *J Med Food.* 2020;23(2):125–131. doi:10.1089/jmf.2019.4414
89. Ai XY, Qin Y, Liu HJ, et al. Apigenin inhibits colonic inflammation and tumorigenesis by suppressing STAT3-NF- κ B signaling. *Oncotarget.* 2017;8(59):100216–100226. doi:10.18632/oncotarget.22145
90. Bian Y. *Protective Effect and Mechanisms of Portulaca Oleracea L. on Experimental Enteritis in Rats Doctor.* China Agricultural University; 2018.
91. Abdelmegid AM, Abdo FK, Ahmed FE, Kattaia AAA. Therapeutic effect of gold nanoparticles on DSS-induced ulcerative colitis in mice with reference to interleukin-17 expression. *Sci Rep.* 2019;9(1):10176. doi:10.1038/s41598-019-46671-1
92. Chen S, Tang A, Zhang T, Huang L, Liu C. Analysis of the effective mechanism of panax notoginseng and portulaca oleracea in treating ulcerative colitis by network pharmacology. *Mod J Integr Traditional Chinese and Western Med.* 2021;30(25):2782–2787+2807.
93. Liu Y. *Study on the Analgesia, Healing and Anti-Inflammation Mechanisms of Simiao Junyi Ointment Based on the Neuroendocrine-Immunoregulatory Network.* Doctor. Hunan University of Traditional Chinese Medicine; 2016.
94. Yang Y, Zhou X, Jia G, et al. Network pharmacology based research into the effect and potential mechanism of *Portulaca oleracea* L. polysaccharide against ulcerative colitis. *Comput Biol Med.* 2023;161:106999. doi:10.1016/j.compbiomed.2023.106999
95. Zhang Z, Yin B, Lian R, et al. Anti-colitis Mechanism of Herba *Portulacae* Based on Network Pharmacology. *World Chin Med.* 2020;15(24):3748–3760.
96. Kim KH, Park EJ, Jang HJ, et al. 1-Carbomethoxy- β -Carboline, derived from *Portulaca oleracea* L. ameliorates LPS-mediated inflammatory response associated with MAPK signaling and nuclear translocation of NF- κ B. *Molecules.* 2019;24(22):4042. doi:10.3390/molecules24224042
97. Miao L, Tao H, Peng Y, et al. The anti-inflammatory potential of *Portulaca oleracea* L. (purslane) extract by partial suppression on NF- κ B and MAPK activation. *Food Chem.* 2019;290:239–245. doi:10.1016/j.foodchem.2019.04.005
98. Kim Y, Lim HJ, Jang HJ, et al. *Portulaca oleracea* extracts and their active compounds ameliorate inflammatory bowel diseases in vitro and in vivo by modulating TNF- α , IL-6 and IL-1 β signalling. *Food Res Int.* 2018;106:335–343. doi:10.1016/j.foodres.2017.12.058

99. Yang X, Yan Y, Li J, et al. Protective effects of ethanol extract from *Portulaca oleracea* L. on dextran sulphate sodium-induced mice ulcerative colitis involving anti-inflammatory and antioxidant. *Am J Transl Res*. 2016;8(5):2138–2148.
100. Yao R, Wei H, Lei J, Wang Z. Progress on the role of mTOR signaling pathway in the pathogenesis and regulatory mechanisms. *Chinese Bulletin of Life Sci*. 2019;31(02):135–142. doi:10.13376/j.cbls/2019020
101. Qiao D, Zhang Z, Zhang Y, et al. Regulation of endoplasmic reticulum stress-autophagy: a potential therapeutic target for ulcerative colitis. *Front Pharmacol*. 2021;12:697360. doi:10.3389/fphar.2021.697360
102. Zhang Z, Qiao D, Zhang Y, et al. *Portulaca oleracea* L. extract ameliorates intestinal inflammation by regulating endoplasmic reticulum stress and autophagy. *Mol Nutr Food Res*. 2022;66(5):e2100791. doi:10.1002/mnfr.202100791
103. Wang F, Song ZY, Qu XJ, et al. M10, a novel derivative of Myricetin, prevents ulcerative colitis and colorectal tumor through attenuating robust endoplasmic reticulum stress. *Carcinogenesis*. 2018;39(7):889–899. doi:10.1093/carcin/bgy057
104. Trivedi PP, Jena GB, Tikoo KB, Kumar V. Melatonin modulated autophagy and Nrf2 signaling pathways in mice with colitis-associated colon carcinogenesis. *Mol, Carcinog*. 2016;55(3):255–267. doi:10.1002/mc.22274
105. Kong R, Luo H, Wang N, et al. *Portulaca* extract attenuates development of dextran sulfate sodium induced colitis in mice through activation of PPAR γ . *PPAR Res*. 2018;2018:6079101. doi:10.1155/2018/6079101
106. Kong R. The mechanism of *portulaca* attenuates development of dextran sulfate sodium induced colitis in mice master. 2018.
107. Liu L, Fan W. Clinical efficacy analysis of purslane capsules combining TCM enema in the treatment of ulcerative colitis. *Modern Chin Med*. 2007;05:6–8.
108. Liu L, Fan W, Zhang J, Zhang R. Treatment of 37 cases of ulcerative colitis with Purslane capsule and Chinese medicine enema. *Shaanxi J Tradition Chin Med*. 2007;10:1323–1325.
109. Ma X, Du X, Fan Z, Liu L. Experience of Professor Liu Li in diagnosis and treatment of ulcerative colitis. *Shandong J Tradition Chin Med*. 2017;36(07):585–587. doi:10.16295/j.cnki.0257-358x.2017.07.015
110. Maimeti A, Maimeti A. Treatment of 32 cases of colitis with compound Purslane and coptis decoction. *J Med Pharm Chin Minorities*. 2009;15(11):29. doi:10.16041/j.cnki.cn15-1175.2009.11.021
111. Wang X, Li Y. Treatment of 41 cases of ulcerative colitis with Purslane decoction. *Guangxi J Tradition Chin Med*. 2006;03:38.
112. Pan A, Yu H, Ren D, Ren J. Observation of therapeutic effect of *Portulaca* decoction on ulcerative colitis. *Lishizhen Medicine and Materia Medica Res*. 2002;06:359.
113. Peng X, Wang X, Wang X. Clinical Observation on 38 cases of ulcerative colitis treated by enema decoction. *J Pract TRADITIONAL CHINESE INTERNAL MED*. 2016;30(06):33–34+37. doi:10.13729/j.issn.1671-7813.2016.06.14
114. Wang M, Lin B, Wei A. Treatment of 68 cases of ulcerative colitis with Jingfang *Portulaca* decoction. *Guangming J Chin Med*. 2010;25(07):1207.
115. Zheng T, Chen T, Cai L, Huang Z. Acute renal failure after eating purslane vegetable: report of 2 cases. *Chinese J Integr Traditional and Western Nephrol*. 2021;22(10):930–931+944.

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>